Back to results
US 7,842,688 B2Granted
Organic compounds
AssigneeNovartis Pharma AG
InventorsPeter Herold, Robert Mah, Stefan Stutz, Aleksandar Stojanovic, Vincenzo Tschinke, Nathalie Jotterand
Life of this patent
Estimating the term…
Abstract
Novel substituted piperidines of the general formulae (I) and (II) with the substituent definitions as explained in detail in the description are described. The compounds are suitable in particular as renin inhibitors and are highly potent.
Claims14
A compound of the formula (I)
- where
- R1 is substituted or unsubstituted dihydro-2H-benzo[1,4]oxazinyl;
- R2 is phenyl substituted by 1-3 halogen, hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, halo-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, cyano-C1-6-alkyl, carboxy-C1-6-alkyl, C1-6-alkanoyloxy-C1-6-alkyl, C1-6-alkoxycarbonyloxy-C1-6-alkyl, C1-6-alkoxycarbonyl, or C1-6-alkoxy groups, or a C1-6-alkylenedioxy group, and/or by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical;
- L1, L2, L3, L4 and L5 are each independently a bond, C1-8-alkylene, C2-8-alkenylene or C2-8-alkynylene, or are absent;
- T1, T2, T3 and T4 are each independently
- (a) a bond, or are absent, or are one of the groups
- (b) —CH(OH)—
- (c) —CH(OR6)—
- (d) —CH(NR5R6)—
- (e) —CO—
- (f) —CR7R8—
- (g) —O— or —NR6—
- (h) —S(O)0-2—
- (I) —SO2NR6—
- (j) —NR6SO2—
- (k) —CONR6—
- (l) —NR6CO—
- (m) —O—CO—
- (n) —CO—O—
- (o) —O—CO—O—
- (p) —O—CO—NR6—
- (q) —N(R6)—CO—N(R6)—
- (r) —N(R6)—CO—O—
- (s) pyrrolidinylene, piperidinylene or piperazinylene
- (t) —C(R11)(R12)—,
- where the bonds starting from (b)-(t) lead to a saturated or aromatic carbon atom of the adjacent group if the bond starts from a heteroatom, and where not more than two (b)-(f) groups, three (g)-(h) groups and one (i)-(t) group are present;
- R3 is hydroxyl, C1-6-alkoxy or C2-6-alkenyloxy;
- R4 is hydrogen;
- R5 and R6 are each independently hydrogen, C1-6-alkyl, C2-6-alkenyl, aryl-C1-6-alkyl or acyl, or, together with the nitrogen atom to which they are bonded, are a 5- or 6-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or a —SO— or —SO2— group, and the additional nitrogen atom may optionally be substituted by C1-6-alkyl radicals;
- R7 and R8, together with the carbon atom to which they are bonded, are a 3-7-membered ring which may contain one or two —O— or —S— atoms or —SO— or —SO2— groups;
- R9 is hydrogen, C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, acyl or arylalkyl;
- R10 is carboxyalkyl, alkoxycarbonylalkyl, alkyl or hydrogen;
- R11 is hydrogen or C1-6-alkyl;
- R12 is hydrogen or C1-6-alkyl;
- U is hydrogen, C1-6-alkyl, C3-8-cycloalkyl, cyano, optionally substituted C3-8-cycloalkyl, aryl, or heterocyclyl;
- Q is absent;
- X is a bond, oxygen or sulphur, or is a >CH—R11, >CHOR9, —O—CO—, >CO, >C═NOR10, —O—CHR11— or —O—CHR11—CO—NR9— group and the bond starting from an oxygen or sulphur atom leads to a saturated carbon atom of the Z group or to R1;
- W is oxygen or sulphur;
- Z is C1-6-alkylene, C2-6-alkenylene, hydroxy-C1-6-alkylidene, —O—, —S—, —O-alk-, —S-alk-, -alk-O—, -alk-S— or -alk-NR9—, where alk is C1-6-alkylene;
- and where
- (a) if Z is —O— or —S—, X is >CH—R11 and either R2 contains an L1-T1-L2-T2-L3-T3-L4-T4-L5-U substituent or R4 is a substituent other than hydrogen as defined above;
- (b) if Z is —O-alk- or —S-alk-, X is >CH—R11;
- and
- (c) if X is a bond, Z is C2-6-alkenylene, -alk-O— or -alk-S—,
- n is 0 or 1;
- m is 0;
- or a pharmaceutically acceptable salt thereof.
44 more elements
A compound according to claim 1, of the formula (IA)
- where R1, R2, R3, R4, Q, W, X, Z, n and m are each as defined for the compounds of the formulae (I) according to claim 11.
Dependencies are inferred from the claim text.